Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has signed an agreement with GMBU e.V., a research organization based in Halle (Saale), Germany, for the technology transfer and scale-up of Astaxanthin production. The technology will be implemented at the company's research facilities in Hyderabad, India. The agreement is a pure technology transfer deal — no shares are being issued, no special rights (such as board seats or share subscription rights) have been granted, and there is no related-party angle. The company has confirmed it is not a related party transaction and no nominee will sit on Novelix's board.
This is a strategic move into Astaxanthin, a high-value antioxidant ingredient used in nutraceuticals, cosmetics, and aquaculture — potentially diversifying Novelix's product pipeline. For shareholders, this could be a positive development if the technology leads to commercial production and new revenue streams, but it is early-stage and carries execution risk with no financial details disclosed yet.